Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Allena Pharmaceuticals (NASDAQ: ALNA) will participate in the 12th Annual Wedbush PacGrow Healthcare Conference from August 10-11, 2021. Louis Brenner, M.D., CEO, will join the Casino Re-nal Part 2 - Cysts and Stones panel on August 11 at 4:05 pm ET. Management will also hold 1x1 meetings during the conference. Allena focuses on developing oral enzyme therapeutics for rare metabolic and kidney disorders. Its lead product, reloxaliase, is in a pivotal Phase 3 clinical program for enteric hyperoxaluria, while ALLN-346 targets hyperuricemia in gout and chronic kidney disease.

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in the upcoming 12^th Annual Wedbush PacGrow Healthcare Conference on August 10^th – August 11^th, 2021.

Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will participate in the Casino Re-nal Part 2 - Cysts and Stones panel discussion. Details for the panel discussion are below:

Casino Re-nal Part 2 - Cysts and Stones Panel
Date:	4:05 pm ET
Time:	Wednesday, August 11th, 2021
Webcast:	https://wsw.com/webcast/wedbush39/panel25/2580370

Management will also be available for 1x1 meetings on Tuesday, August 10^th – Wednesday, August 11^th, 2021.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study recently completed and a Phase 2a program planned for the second half of 2021.

Investor Contact
Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
arr@lifesciadvisors.com

Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

FAQ

What conference will Allena Pharmaceuticals participate in August 2021?

Allena Pharmaceuticals will participate in the 12th Annual Wedbush PacGrow Healthcare Conference from August 10-11, 2021.

Who from Allena Pharmaceuticals will speak at the Wedbush conference?

Louis Brenner, M.D., CEO of Allena Pharmaceuticals, will speak at the Casino Re-nal Part 2 - Cysts and Stones panel.

What is the focus of Allena Pharmaceuticals' lead product, reloxaliase?

Reloxaliase, Allena Pharmaceuticals' lead product, targets enteric hyperoxaluria, a condition linked to high urinary oxalate levels and kidney stones.

When is the Casino Re-nal Part 2 panel discussion scheduled?

The Casino Re-nal Part 2 panel discussion is scheduled for August 11, 2021, at 4:05 pm ET.

What is the ticker symbol for Allena Pharmaceuticals?

The ticker symbol for Allena Pharmaceuticals is ALNA.